Log in

Biotech Erytech Pharma wants to enter the US stock market

The Lyon-based biopharmaceutical company Erytech Pharma said on the night of Friday to Saturday to have filed an application for registration with the US stock exchange to enter the Nasdaq.

"The number of shares to be offered and the price range for the proposed global offer may only be determined at the end of a period of 15 days following the filing of the registration form, already listed in France, in a press release.

The biotech plans to use the sums raised after the IPO to conduct a Phase III clinical study (involving a large number of patients) on the efficacy of its flagship molecule, "eryaspase", in the treatment of pancreatic cancer in the United States and Europe "as well as for other clinical and preclinical development programs."

The launch of this study is "considered in the course of the 3th quarter 2018", announces in addition the group of Lyon.

In March, the company announced a therapeutic breakthrough of "eryaspase" (commercial name: Graspa) in the fight against pancreatic cancer, a very aggressive type of cancer against which medicine is deprived.

The use of Graspa coupled with chemotherapy allows "significant advances in both progression-free survival (disease) and overall survival in treated patients," explained the biotech.

In mid-April, it raised 70,5 million euros in a private placement of securities with US and European investors, half of which was to finance the pre-launch of the Phase III.

This fund-raising, which has allowed the company to strengthen its own funds, will also fund clinical studies on the efficacy of eryaspase on forms of acute leukemia, it also mentioned in the release.

Founded in Lyon in 2004, Erytech is a biopharmaceutical company that develops innovative therapies to fight against rare forms of cancer and orphan diseases.

a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb - drapeauitalie )

  group    administrators A3P
& Project Managers

letter   newsletter A3P